Atherosclerosis
Volume 196, Issue 2 , Pages 497-504 , February 2008

Ceramide: A common pathway for atherosclerosis?

  • Jean Bismuth
    • ,
  • Peter Lin
    • ,
  • Qizhi Yao
    • ,
  • Changyi Chen

      Affiliations

    • Corresponding Author InformationCorresponding author at: Michael E. DeBakey Department of Surgery, Baylor College of Medicine, One Baylor Plaza, Mail Stop: NAB-2010, Houston, TX 77030, United States. Tel.: +1 713 798 4401; fax: +1 713 798 6633.

Received 4 February 2007 ,Revised 8 September 2007 ,Accepted 13 September 2007.

References 

  1. Jiang XC, Paultre F, Pearson TA, et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol. 2000;20:2614–2618
  2. Schissel SL, Tweedie-Hardman J, Rapp JH, et al. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest. 1996;98:1455–1464
  3. Li Z, Basterr MJ, Hailemariam TK, et al. The effect of dietary sphingolipids on plasma sphingomyelin metabolism and atherosclerosis. Biochim Biophys Acta. 2005;1735:130–134
  4. Tabas I, Li Y, Brocia RW, et al. Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation. J Biol Chem. 1993;268:20419–20432
  5. Schissel SL, Jiang X, Tweedie-Hardman J, et al. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J Biol Chem. 1998;273:2738–2746
  6. Xu XX, Tabas I. Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesteryl ester accumulation in macrophages. J Biol Chem. 1991;266:24849–24858
  7. Kolesnick RN. Sphingomyelin and derivatives as cellular signals. Prog Lipid Res. 1991;30:1–38
  8. Spiegel S, Merrill AH. Sphingolipid metabolism and cell growth regulation. FASEB J. 1996;10:1388–1397
  9. Merrill AH, Schmelz EM, Dillehay DL, et al. Sphingolipids—the enigmatic lipid class: biochemistry, physiology, and pathophysiology. Toxicol Appl Pharmacol. 1997;142:208–225
  10. Marchesini N, Hannun YA. Acid and neutral sphingomyelinases: roles and mechanisms of regulation. Biochem Cell Biol. 2004;82:27–44
  11. Futerman AH, van Meer G. The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol. 2004;5:554–565
  12. Jeong T, Schissel SL, Tabas I, et al. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J Clin Invest. 1998;101:905–912
  13. Hoff HF, Morton RE. Lipoproteins containing apo B extracted from human aortas. Structure and function. Ann N Y Acad Sci. 1985;454:183–194
  14. Chatterjee S. Sphingolipids in atherosclerosis and vascular biology. Arterioscler Thromb Vasc Biol. 1998;18:1523–1533
  15. Chatterjee S, Kwiterovich PO. Glycosphingolipids of human plasma lipoproteins. Lipids. 1976;11:462–466
  16. Dawson G, Kruski AW, Scanu AM. Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976;17:125–131
  17. Prokazova NV, Mukhin DN, Orekhov AN, et al. Neutral glycolipids of atherosclerotic plaques and unaffected human aorta tissue. Eur J Biochem. 1989;180:167–171
  18. Ichi I, Nakahara K, Kiso K, Kojo S. Effect of dietary cholesterol and high fat on ceramide concentration in rat tissues. Nutrition. 2007;23:570–574
  19. Grandl M, Bared SM, Liebisch G, et al. E-LDL and Ox-LDL differentially regulate ceramide and cholesterol raft microdomains in human macrophages. Cytometry A. 2006;69:189–191
  20. Arimoto I, Saito H, Kawashima Y, et al. Effects of sphingomyelin and cholesterol on lipoprotein lipase-mediated lipolysis in lipid emulsions. J Lipid Res. 1998;39:143–151
  21. Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation. 1997;96:3042–3047
  22. Nakamura M, Yoshida H, Arakawa N, et al. Effects of tumor necrosis factor-alpha on basal and stimulated endothelium-dependent vasomotion in human resistance vessel. J Cardiovasc Pharmacol. 2000;36:487–492
  23. Wang P, Ba ZF, Chaudry IH. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol. 1994;266:H2535–H2541
  24. Xu J, Yeh CH, Chen S, et al. Involvement of de novo ceramide biosynthesis in tumor necrosis factor-alpha/cycloheximide-induced cerebral endothelial cell death. J Biol Chem. 1998;273:16521–16526
  25. Modur V, Zimmerman GA, Prescott SM, McIntyre TM. Endothelial cell inflammatory responses to tumor necrosis factor alpha. Ceramide-dependent and -independent mitogen-activated protein kinase cascades. J Biol Chem. 1996;271:13094–13102
  26. Sawada M, Kiyono T, Nakashima S, et al. Molecular mechanisms of TNF-alpha-induced ceramide formation in human glioma cells: P53-mediated oxidant stress-dependent and -independent pathways. Cell Death Differ. 2004;11:997–1008
  27. Hannun YA. Functions of ceramide in coordinating cellular responses to stress. Science. 1996;274:1855–1859
  28. Liu B, Andrieu-Abadie N, Levade T, et al. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J Biol Chem. 1998;273:11313–11320
  29. Singh I, Pahan K, Khan M, Singh AK. Cytokine-mediated induction of ceramide production is redox-sensitive. J Biol Chem. 1998;273:20354–20362
  30. Garcia-Ruiz C, Colell A, Mari M, et al. Direct effects of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species. J Biol Chem. 1997;272:11369–11377
  31. Zhang DX, Zou AP, Li PL. Ceramide-induced activation of NADPH oxidase and endothelial dysfunction in small coronary arteries. Am J Physiol Heart Circ Physiol. 2003;284:H605–H612
  32. Zhang DX, Fryer RM, Hsu AK, et al. Production and metabolism of ceramide in normal and ischemic-reperfused myocardium of rats. Basic Res Cardiol. 2001;96:267–274
  33. Memon RA, Bass NM, Moser AH, et al. Down-regulation of liver and heart specific fatty acid binding proteins by endotoxin and cytokines in vivo. Biochim Biophys Acta. 1999;1440:118–126
  34. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89:763–771
  35. Hirokawa M, Kitabayashi A, Kuroki J, Miura AB. Induction of tissue factor production but not the upregulation of adhesion molecule expression by ceramide in human vascular endothelial cells. Tohoku J Exp Med. 2000;191:167–176
  36. Gu Q, Yang XP, Bonde P, et al. Inhibition of TNF-alpha reduces myocardial injury and proinflammatory pathways following ischemia-reperfusion in the dog. J Cardiovasc Pharmacol. 2006;48:320–328
  37. Siragy HM, Xue C, Webb RL. Beneficial effects of combined benazepril-amlodipine on cardiac nitric oxide, cGMP, and TNF-alpha production after cardiac ischemia. J Cardiovasc Pharmacol. 2006;47:636–642
  38. Csiszar A, Labinskyy N, Smith K, et al. Vasculoprotective effects of anti-tumor necrosis factor-{alpha} treatment in aging. Am J Path. 2007;170:388–398
  39. Csiszar A, Smith K, Labinskyy N, et al. Resveratrol attenuates TNF-alpha-induced activation of coronary arterial endothelial cells: role of NF-kappaB inhibition. Am J Physiol Heart Circ Physiol. 2006;291:H1694–H1699
  40. Ito H, Koide N, Hassan F, et al. Lethal endotoxic shock using alpha-galactosylceramide sensitization as a new experimental model of septic shock. Lab Invest. 2006;86:254–261
  41. Hürlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation. 2002;106:2184–2187
  42. Booth AD, Jayne DR, Kharbanda RK, et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation. 2004;109:1718–1723
  43. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997;277:1775–1781
  44. Taylor LM, Moneta GL, Sexton GJ, et al. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg. 1999;29:8–19
  45. Yang ZZ, Zou AP. Homocysteine enhances TIMP-1 expression and cell proliferation associated with NADH oxidase in rat mesangial cells. Kidney Int. 2003;63:1012–1020
  46. Yi F, Zhang AY, Janscha JL, et al. Homocysteine activates NADH/NADPH oxidase through ceramide-stimulated Rac GTPase activity in rat mesangial cells. Kidney Int. 2004;66:1977–1987
  47. Yi F, Zhang AY, Li N, et al. Inhibition of ceramide-redox signaling pathway blocks glomerular injury in hyperhomocysteinemic rats. Kidney Int. 2006;70:88–96
  48. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90:251–262
  49. Ikeda U, Shimada K. Matrix metalloproteinases and coronary artery diseases. Clin Cardiol. 2003;26:55–59
  50. Lijnen HR. Extracellular proteolysis in the development and progression of atherosclerosis. Biochem Soc Trans. 2002;30:163–167
  51. Xu XP, Meisel SR, Ong JM, et al. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation. 1999;99:993–998
  52. Rajavashisth TB, Liao JK, Galis ZS, et al. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem. 1999;274(April):11924–11929
  53. Huang Y, Song L, Wu S, et al. Oxidized LDL differentially regulates MMP-1 and TIMP-1 expression in vascular endothelial cells. Atherosclerosis. 2001;156:119–125
  54. Auge N, Maupas-Schwalm F, Elbaz M, et al. Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation. Circulation. 2004;110:571–578
  55. Izgi C, Cevik C, Ozkan M, et al. Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation. Circulation. 2005;111:e38–e39
  56. Huwiler A, Kolter T, Pfeilschifter J, Sandhoff K. Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta. 2000;31(1485):63–99
  57. Hernandez OM, Discher DJ, Bishopric NH, Webster K. Rapid activation of neutral sphingomyelinase by hypoxia-reoxygenation of cardiac myocytes. Circ Res. 2000;86:198–204
  58. Li H, Junk P, Huwiler A, et al. Dual effect of ceramide on human endothelial cells: induction of oxidative stress and transcriptional upregulation of endothelial nitric oxide synthase. Circulation. 2002;106:2250–2256
  59. Yeh LH, Kinsey AM, Chatterjee S, Alevriadou BR. Lactosylceramide mediates shear-induced endothelial superoxide production and intercellular adhesion molecule-1 expression. J Vas Res. 2001;38:551–559
  60. Williams RD, Wang E, Merrill AH. Enzymology of long-chain base synthesis by liver: characterization of serine palmitoyltransferase in rat liver microsomes. Arch Biochem Biophys. 1984;228:282–291
  61. Pchejetski D, Kunduzova O, Dayon A, et al. Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis. Circ Res. 2007;100:41–49
  62. Bielawska AE, Shapiro JP, Jiang L, et al. Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion. Am J Path. 1997;151:1257–1263
  63. Bandyopadhyay D, Chattopadhyay A, Ghosh G, Datta AG. Oxidative stress-induced ischemic heart disease: protection by antioxidants. Cur Med Chem. 2004;11:369–387
  64. Bolli R. Basic and clinical aspects of myocardial stunning. Prog Cardiovasc Dis. 1998;40:477–516
  65. Kunduzova OR, Bianchi P, Parini A, Cambon C. Hydrogen peroxide production by monoamine oxidase during ischemia/reperfusion. Eur J Pharm. 2002;448:225–230
  66. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nature Rev. 2003;4:397–407
  67. Karliner JS, Honbo N, Summers K, et al. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J Mol Cell Cardiol. 2001;33:1713–1717
  68. Olivera A, Kohama T, Edsall L, et al. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J Cell Biol. 1999;147:545–558
  69. Jin ZQ, Goetzl EJ, Karliner JS. Sphingosine kinase activation mediates ischemic preconditioning in murine heart. Circulation. 2004;110:1980–1989
  70. Zhang DX, Zou AP, Li PL. Ceramide reduces endothelium-dependent vasodilation by increasing superoxide production in small bovine coronary arteries. Circ Res. 2001;88:824–831
  71. Mogami K, Kishi H, Kobayashi S. Sphingomyelinase causes endothelium-dependent vasorelaxation through endothelial nitric oxide production without cytosolic Ca(2+) elevation. FEBS Lett. 2005;579:393–397
  72. Igarashi J, Thatte HS, Prabhakar P, Golan DE, Michel T. Calcium-independent activation of endothelial nitric oxide synthase by ceramide. Proc Natl Acad Sci U S A. 1999;96:12583–12588
  73. Bulotta S, Barsacchi R, Rotiroti D, et al. Activation of the endothelial nitric-oxide synthase by tumor necrosis factor-α. A novel feedback mechanism regulating cell death. J Biol Chem. 2001;276:6529–6536
  74. Igarashi J, Thatte HS, Prabhakar P, et al. Calcium-independent activation of endothelial nitric oxide synthase by ceramide. Proc Natl Acad Sci U S A. 1999;96:12583–12588
  75. Bhunia AK, Han H, Snowden A, Chatterjee S. Redox-regulated signaling by lactosylceramide in the proliferation of human aortic smooth muscle cells. J Biol Chem. 1997;272:15642–15649
  76. Harada-Shiba M, Kinoshita M, Kamido H, Shimokado K. Oxidized low density lipoprotein induces apoptosis in cultured human umbilical vein endothelial cells by common and unique mechanisms. J Biol Chem. 1998;273:9681–9687
  77. Hein TW, Kuo L. LDLs impair vasomotor function of the coronary microcirculation: role of superoxide anions. Circ Res. 1998;83:404–414
  78. Merrill AH, Wang E, Stevens J, Brumley GW. Activities of the initial enzymes of glycerolipid and sphingolipid synthesis in lung microsomes from rats exposed to air or 85% oxygen. Biochem Biophys Res Commun. 1984;119:995–1000
  79. Williams RD, Sgoutas DS, Zaatari GS. Enzymology of long-chain base synthesis by aorta: induction of serine palmitoyltransferase activity in rabbit aorta during atherogenesis. J Lipid Res. 1986;27:763–770
  80. Fujita T, Inoue K, Yamamoto S, et al. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiotics. 1994;47:208–215
  81. Chen JK, Lane WS, Schreiber SL. The identification of myriocin-binding proteins. Chem Biol. 1999;6:221–235
  82. Park TS, Panek RL, Mueller SB, et al. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation. 2004;110:3465–3471
  83. Park TS, Panek RL, Rekhter MD, et al. Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice. Atherosclerosis. 2006;189:264–272
  84. Hojjati MR, Li Z, Zhou H, et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem. 2005;280:10284–10289
  85. Nordestgaard BG, Gronholdt ML, Sillesen H. Echolucent rupture-prone plaques. Curr Opin Lipidol. 2003;14:505–512
  86. Tabas I. Sphingolipids and atherosclerosis: a mechanistic connection? A therapeutic opportunity?. Circulation. 2004;110:3400–3401
  87. Li JJ, Zheng X, Li J. Statins may be beneficial for patients with slow coronary flow syndrome due to its anti-inflammatory property. Med Hypotheses. 2007;69:333–337
  88. Osto E, Coppolino G, Volpe M, Cosentino F. Restoring the dysfunctional endothelium. Curr Pharm Des. 2007;13:1053–1068
  89. Chen SD, Hu CJ, Yang DI, et al. Pravastatin attenuates ceramide-induced cytotoxicity in mouse cerebral endothelial cells with HIF-1 activation and VEGF upregulation. Ann N Y Acad Sci. 2005;1042:357–364
  90. Mathias S, Pena LA, Kolesnick RN. Signal transduction of stress via ceramide. Biochem J. 1998;335:465–480
  91. Brenner B, Koppenhoefer U, Weinstock C, et al. Fas- or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153. J Biol Chem. 1997;272:22173–22181
  92. Shabahang S, Liu YH, Huwiler A, Pfeilschifter J. Identification of the LIM kinase-1 as a ceramide-regulated gene in renal mesangial cells. Biochem Biophys Res Commun. 2002;298:408–413

PII: S0021-9150(07)00558-8

doi: 10.1016/j.atherosclerosis.2007.09.018

Atherosclerosis
Volume 196, Issue 2 , Pages 497-504 , February 2008

Article Tools

* Image Usage & Resolution